These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 8368328)

  • 1. Apoprotein-based synthetic surfactants inhibit plasmic cleavage of fibrinogen in vitro.
    Günther A; Bleyl H; Seeger W
    Am J Physiol; 1993 Aug; 265(2 Pt 1):L186-92. PubMed ID: 8368328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential sensitivity to fibrinogen inhibition of SP-C- vs. SP-B-based surfactants.
    Seeger W; Günther A; Thede C
    Am J Physiol; 1992 Mar; 262(3 Pt 1):L286-91. PubMed ID: 1550251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surface properties and sensitivity to protein-inhibition of a recombinant apoprotein C-based phospholipid mixture in vitro--comparison to natural surfactant.
    Seeger W; Thede C; Günther A; Grube C
    Biochim Biophys Acta; 1991 Jan; 1081(1):45-52. PubMed ID: 1991155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinolysis-inhibitory capacity of clot-embedded surfactant is enhanced by SP-B and SP-C.
    Markart P; Ruppert C; Grimminger F; Seeger W; Günther A
    Am J Physiol Lung Cell Mol Physiol; 2003 Jan; 284(1):L69-76. PubMed ID: 12388357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
    Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clot-embedded natural surfactant: kinetics of fibrinolysis and surface activity.
    Günther A; Kalinowski M; Elssner A; Seeger W
    Am J Physiol; 1994 Nov; 267(5 Pt 1):L618-24. PubMed ID: 7977772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations.
    Seeger W; Grube C; Günther A; Schmidt R
    Eur Respir J; 1993 Jul; 6(7):971-7. PubMed ID: 8370446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surfactant incorporation markedly alters mechanical properties of a fibrin clot.
    Günther A; Kalinowski M; Rosseau S; Seeger W
    Am J Respir Cell Mol Biol; 1995 Dec; 13(6):712-8. PubMed ID: 7576709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteolytic cleavage of fibrinogen: amplification of its surfactant inhibitory capacity.
    Seeger W; Grube C; Günther A
    Am J Respir Cell Mol Biol; 1993 Sep; 9(3):239-47. PubMed ID: 8398160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biophysical inhibition of synthetic phospholipid-lung surfactant apoprotein admixtures by plasma proteins.
    Venkitaraman AR; Baatz JE; Whitsett JA; Hall SB; Notter RH
    Chem Phys Lipids; 1991; 57(1):49-57. PubMed ID: 2060063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biophysical inhibition of synthetic vs. naturally-derived pulmonary surfactant preparations by polymeric nanoparticles.
    Beck-Broichsitter M; Ruppert C; Schmehl T; Günther A; Seeger W
    Biochim Biophys Acta; 2014 Jan; 1838(1 Pt B):474-81. PubMed ID: 24184425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of fibrinogen degradation products and lung ground substance on surfactant function.
    O'Brodovich HM; Weitz JI; Possmayer F
    Biol Neonate; 1990; 57(6):325-33. PubMed ID: 2142607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactants.
    Hall SB; Venkitaraman AR; Whitsett JA; Holm BA; Notter RH
    Am Rev Respir Dis; 1992 Jan; 145(1):24-30. PubMed ID: 1731593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An ethanol/ether soluble apoprotein from rat lung surfactant augments liposome uptake by isolated granular pneumocytes.
    Claypool WD; Wang DL; Chander A; Fisher AB
    J Clin Invest; 1984 Sep; 74(3):677-84. PubMed ID: 6547963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recent advances in molecular biology with respect to pulmonary surfactant apoproteins].
    Kuroki Y; Ogasawara Y
    Nihon Rinsho; 1996 Feb; 54(2):334-40. PubMed ID: 8838078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surfactant protein B and C analogues.
    Walther FJ; Gordon LM; Zasadzinski JA; Sherman MA; Waring AJ
    Mol Genet Metab; 2000; 71(1-2):342-51. PubMed ID: 11001826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of synthetic peptides in the formation of biophysically and biologically active pulmonary surfactants.
    Revak SD; Merritt TA; Hallman M; Heldt G; La Polla RJ; Hoey K; Houghten RA; Cochrane CG
    Pediatr Res; 1991 May; 29(5):460-5. PubMed ID: 1896249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surfactant apoprotein A modifies the inhibitory effect of plasma proteins on surfactant activity in vivo.
    Yukitake K; Brown CL; Schlueter MA; Clements JA; Hawgood S
    Pediatr Res; 1995 Jan; 37(1):21-5. PubMed ID: 7700729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung function, surfactant apoprotein content, and level of PEEP in prematurely delivered rabbits.
    Ogawa A; Brown CL; Schlueter MA; Benson BJ; Clements JA; Hawgood S
    J Appl Physiol (1985); 1994 Oct; 77(4):1840-9. PubMed ID: 7836208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A coagulative type of pulmonary surfactant depletion--a mechanism of damage to the pulmonary surfactant system].
    Koga Y
    Hokkaido Igaku Zasshi; 1994 May; 69(3):434-44. PubMed ID: 7927172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.